Opiant Pharmaceuticals Announces First Subjects Dosed in Study Comparing OPNT003, Nasal Nalmefene, With Nasal Naloxone

NEXT STORY
HTG Molecular Diagnostics Reports Preliminary First Quarter 2021 Financial Results
PREV STORY
Quebec Media Personality Julie Snyder is Dreaming Big to End Women’s Cancers
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Reneo Pharmaceuticals Appoints Vineet R. Jindal as Chief Financial Officer

author_avatar
NASDAQ Market News

Sorrento Therapeutics Announces Proposed Public Offering of Common Stock and Warrants

author_avatar
NASDAQ Market News

Global $56.15 Bn Antibiotics Markets to 2026: Focus on Cephalosporins, Penicillins, Fluoroquinolones, Macrolides, Carbapenems, Aminoglycosides, Sulfonamides

author_avatar
NASDAQ Market News